Kliniczny Szpital Wojewodzki Nr 2 Im. Sw. Jadwigi Krolowej W Rzeszowie
- Address
- lock Available on a paid plan
Pediatric Oncology
The department focuses on acute lymphoblastic leukemia, lymphoblastic lymphoma and myeloid leukemia in children, aiming to improve survival by testing novel immunotherapies and optimizing chemotherapy regimens.
- Targeted immunotherapy approaches
- Proteasome inhibition strategies
- Genetic risk‑adapted treatment
- Reduction of treatment‑related toxicities
Collaborative trials with the AIEOP‑BFM network enhance trial enrollment at Kliniczny Szpital Wojewodzki Nr 2.
Endocrinology & Growth Disorders
Research addresses growth hormone deficiency, short stature due to Turner, Noonan or small‑for‑gestational‑age origins, and congenital adrenal hyperplasia, evaluating new hormone therapies and dosage regimens to support normal growth.
- Comparison of weekly versus daily growth hormone delivery
- Adrenal steroid suppression assessment
- Genetic diagnostics for growth failure
- Long‑term safety of hormone replacement
The II Klinika Pediatrii, Endokrynologii i Diabetologii Dzieciecej leads these pediatric endocrine studies.
Metabolic & Obesity Research
Trials target obesity and its metabolic complications, including type 2 diabetes and early type 1 diabetes, testing agents that sustain weight loss and improve glycemic control in adolescents.
- Weight‑management drug efficacy
- Beta‑cell preservation in recent‑onset diabetes
- Maintenance of BMI after initial loss
- Metabolic risk reduction strategies
Studies incorporate the site’s expertise in pediatric metabolism and nutrition.
Cardiovascular & Heart Failure
Investigations include patients with acute myocardial infarction and chronic heart failure, evaluating anti‑inflammatory agents, SGLT2 inhibitors, and novel biomarkers to lower cardiovascular events and improve quality of life.
- IL‑6 pathway blockade after myocardial infarction
- SGLT2 inhibitor impact on worsening heart failure
- Thrombolysis safety in anticoagulated stroke patients
- Biomarker‑guided therapeutic decisions
The ARTEMIS trial of ziltivekimab exemplifies the site’s cardiovascular research portfolio.
Infectious Diseases & Antibiotics
The center evaluates treatments for complicated urinary tract infection, acute pyelonephritis and other serious bacterial infections in children, focusing on safety, pharmacokinetics and resistance patterns.
- Safety of new IV antimicrobials in pediatrics
- Oral antibiotic pharmacokinetic profiling
- Management of neonatal respiratory infections
- Surveillance of antimicrobial resistance
Vabomere (meropenem‑vaborbactam) studies are conducted under the hospital’s infectious‑disease protocol.
Autoimmune & Lupus Nephritis
Clinical work explores systemic lupus erythematosus and lupus nephritis, testing biologics such as anifrolumab and ianalumab to achieve renal remission and disease control.
- IL‑6 and interferon pathway inhibition
- B‑cell depletion strategies
- Complete renal response endpoints
- Long‑term safety of targeted therapies
The SRI‑4 outcome measure guides efficacy assessment in SLE trials.
Neurology & Stroke
Research includes patients with acute ischemic stroke, assessing reperfusion techniques, reversal agents for anticoagulation, and functional outcomes after treatment.
- Thrombolysis with rtPA in DOAC‑reversed patients
- Functional recovery measured by modified Rankin scale
- Safety of anticoagulant antidotes
- Imaging biomarkers for early prognosis
The STROACT study provides critical data on stroke management in anticoagulated populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 14 therapeutic areas and 15 of 77 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 75 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1GPOH gGmbH2active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S6trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kliniczny Szpital Wojewodzki Nr 2 Im. Sw. Jadwigi Krolowej W Rzeszowie
lock Showing 1 of 29 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of Somapacitan and Somatropin in Pediatric Patients with Short Stature Due to SGA, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature | Novo Nordisk A/S | Phase III | Not Recruiting | Aug 2022 | — |
IMP list
lock Showing 1 of 77 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 7 | Unknown | 2017-10-02 | 2024-11-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.